Acknowledgement
This research was supported by a fund (code: 2022-ER0507-00) by Research of Korea Disease Control and Prevention Agency.
References
- Rapezzi C, Quarta CC, Riva L, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol 2010;7:398-408. https://doi.org/10.1038/nrcardio.2010.67
- Kim D, Choi JO, Kim K, Kim SJ, Jeon ES. Untangling amyloidosis: recent advances in cardiac amyloidosis. Int J Heart Fail 2020;2:231-9. https://doi.org/10.36628/ijhf.2020.0016
- Maurer MS, Hanna M, Grogan M, et al. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol 2016;68:161-72. https://doi.org/10.1016/j.jacc.2016.03.596
- Damy T, Kristen AV, Suhr OB, et al. Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS). Eur Heart J 2019;43:391-400. https://doi.org/10.1093/eurheartj/ehz173
- Connors LH, Sam F, Skinner M, et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study. Circulation 2016;133:282-90. https://doi.org/10.1161/CIRCULATIONAHA.115.018852